Alkermes ALKS
NASDAQ ALKS
$45.37 -0.13 (-0.27%)
As of: Sep 9, 2026 · 3:26 PM EDT

Alkermes (ALKS) Share-based Compensation (2010 - 2026)

Alkermes' (ALKS) quarterly Share-based Compensation came in at $31.1 million in Q2 2026, up 24.73% year-over-year from $25.0 million in Q2 2025, and up 98.16% quarter-over-quarter from $15.7 million in Q1 2026.

Analysis

Alkermes (ALKS) Share-based Compensation (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Share-based Compensation for 17 consecutive years, with $31.1 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Share-based Compensation rose 24.73% year-over-year to $31.1 million in Q2 2026; TTM through Jun 2026 was $73.8 million, a 8.68% decrease from a year earlier, with the FY2025 full-year figure at $98.7 million, up 2.15% from the prior year.
  • Share-based Compensation was $31.1 million for Q2 2026 at Alkermes, up from $15.7 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $31.1 million in Q2 2026 and troughed at $622000.0 in Q3 2025.
  • A 5-year average of $15.4 million and a median of $16.0 million in 2022 frame the typical range for Share-based Compensation.
  • The widest YoY moves for Share-based Compensation: up 857.65% in 2025, down 88.73% in 2025.
  • Over 5 years, Share-based Compensation stood at $3.3 million in 2022, then jumped by 683.12% to $25.8 million in 2023, then dropped by 19.72% to $20.7 million in 2024, then climbed by 26.64% to $26.3 million in 2025, then grew by 18.51% to $31.1 million in 2026.
  • The last three Share-based Compensation figures came in at $31.1 million (Q2 2026), $15.7 million (Q1 2026), and $26.3 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Johnson & Johnson 645.93 Bn 625.17 Bn 17.26 Bn -950.00 Mn
2 AbbVie 443.06 Bn 436.49 Bn 12.70 Bn 166.00 Mn
3 Merck 365.76 Bn 358.62 Bn 12.21 Bn 298.00 Mn
4 Novartis Ag 266.47 Bn 258.78 Bn 11.24 Bn -
5 Pfizer 158.57 Bn 146.88 Bn 10.94 Bn 249.00 Mn
6 Sanofi 52.36 Bn 44.98 Bn 10.79 Bn -
7 Revolution Medicines 43.97 Bn 43.97 Bn - 277.20 Mn
8 Incyte 25.42 Bn 20.88 Bn 1.57 Bn 67.26 Mn
9 United Therapeutics 21.52 Bn 18.86 Bn 683.80 Mn 19.00 Mn
10 Alkermes 7.58 Bn 6.93 Bn 397.90 Mn 31.14 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 31.14 Mn
Mar 31, 2026 15.71 Mn
Dec 31, 2025 26.28 Mn
Sep 30, 2025 622,000.00
Jun 30, 2025 24.97 Mn
Mar 31, 2025 29.53 Mn
Dec 31, 2024 20.75 Mn
Sep 30, 2024 5.52 Mn
Jun 30, 2024 2.61 Mn
Mar 31, 2024 11.23 Mn
Dec 31, 2023 25.84 Mn
Sep 30, 2023 23.92 Mn
Jun 30, 2023 9.13 Mn
Mar 31, 2023 2.87 Mn
Dec 31, 2022 3.30 Mn
Sep 30, 2022 26.05 Mn
Jun 30, 2022 16.20 Mn
Mar 31, 2022 1.80 Mn
Dec 31, 2021 19.02 Mn
Sep 30, 2021 25.60 Mn